Cargando…

Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study

After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Siqueira, Patricia F. R., Fleury, Marcos K., Pontes, Robéria M., Silva, Renata S. P., Costa, Elaine S., Land, Marcelo G. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777031/
https://www.ncbi.nlm.nih.gov/pubmed/36553015
http://dx.doi.org/10.3390/diagnostics12123008
_version_ 1784856004625694720
author Siqueira, Patricia F. R.
Fleury, Marcos K.
Pontes, Robéria M.
Silva, Renata S. P.
Costa, Elaine S.
Land, Marcelo G. P.
author_facet Siqueira, Patricia F. R.
Fleury, Marcos K.
Pontes, Robéria M.
Silva, Renata S. P.
Costa, Elaine S.
Land, Marcelo G. P.
author_sort Siqueira, Patricia F. R.
collection PubMed
description After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have developed and validated a new decision tool to predict the presence of two or more deletions of α-thalassemia, increasing considerably the pre-test probability. The model was created using the variables: the percentage of HbA(2), serum ferritin and mean corpuscular volume standardized by age. The model was trained in 134 patients and validated in 160 randomly selected patients from the total sample. We used Youden’s index applied to the ROC curve methodology to establish the optimal odds ratio (OR) cut-off for the presence of two or more α-globin gene deletions. Using the OR cut-off of 0.4, the model’s negative predictive value (NPV) was 96.8%; the cut-off point accuracy was 85.4%; and the molecular analysis pre-test probability increased from 25.9% to 65.4% after the use of the proposed model. This tool aims to assist the physician in deciding when to perform molecular studies for the diagnosis of α-thalassemia. The model is useful in places with few financial health resources.
format Online
Article
Text
id pubmed-9777031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97770312022-12-23 Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study Siqueira, Patricia F. R. Fleury, Marcos K. Pontes, Robéria M. Silva, Renata S. P. Costa, Elaine S. Land, Marcelo G. P. Diagnostics (Basel) Article After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have developed and validated a new decision tool to predict the presence of two or more deletions of α-thalassemia, increasing considerably the pre-test probability. The model was created using the variables: the percentage of HbA(2), serum ferritin and mean corpuscular volume standardized by age. The model was trained in 134 patients and validated in 160 randomly selected patients from the total sample. We used Youden’s index applied to the ROC curve methodology to establish the optimal odds ratio (OR) cut-off for the presence of two or more α-globin gene deletions. Using the OR cut-off of 0.4, the model’s negative predictive value (NPV) was 96.8%; the cut-off point accuracy was 85.4%; and the molecular analysis pre-test probability increased from 25.9% to 65.4% after the use of the proposed model. This tool aims to assist the physician in deciding when to perform molecular studies for the diagnosis of α-thalassemia. The model is useful in places with few financial health resources. MDPI 2022-12-01 /pmc/articles/PMC9777031/ /pubmed/36553015 http://dx.doi.org/10.3390/diagnostics12123008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Siqueira, Patricia F. R.
Fleury, Marcos K.
Pontes, Robéria M.
Silva, Renata S. P.
Costa, Elaine S.
Land, Marcelo G. P.
Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title_full Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title_fullStr Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title_full_unstemmed Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title_short Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
title_sort novel decision tool for more severe α-thalassemia genotypes screening with functional loss of two or more α-globin genes: a diagnostic test study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777031/
https://www.ncbi.nlm.nih.gov/pubmed/36553015
http://dx.doi.org/10.3390/diagnostics12123008
work_keys_str_mv AT siqueirapatriciafr noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy
AT fleurymarcosk noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy
AT pontesroberiam noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy
AT silvarenatasp noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy
AT costaelaines noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy
AT landmarcelogp noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy